REGENXBIO Inc. - 10-Q Filing

REGENXBIO Inc. reports Q3 2026 financial results including royalty revenue from GlaxoSmithKline and Nippon Shinyaku collaborations.

SEC EDGAR ·

Tickers: $RGNX

Read the full article at SEC EDGAR

More Regulatory news